Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Sustained Minimal Symptom Expression in Generalized Myasthenia Gravis: A 120-week Post Hoc Analysis of RAISE-XT

Ofatumumab Treatment Up to Eight Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis